SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chariot P, Monnet I, Mouchet M, Rohr M, Lefaucheur JP, Dubreuil-Lemaire ML, et al. Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum 1994; 37: 5836.
  • 2
    Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 50810.
  • 3
    Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322: 1098105.
  • 4
    Lewis W, Gonzalez B, Chomyn A, Papoian T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 1992; 89: 135460.
  • 5
    Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685708.
  • 6
    Rylova SN, Albertioni F, Flygh G, Eriksson S. Activity profiles of deoxynucleoside kinases and 5′-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochem Pharmacol 2005; 69: 95160.
  • 7
    Lynx MD, McKee EE. 3′-azido-3′-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 2006; 72: 23943.
  • 8
    Susan-Resiga D, Bentley AT, Lynx MD, LaClair DD, McKee EE. Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart. Antimicrob Agents Chemother 2007; 51: 11429.
  • 9
    De la Asuncion JG, del Olmo ML, Sastre J, Millan A, Pellin A, Pallardo FV, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria: prevention by antioxidant vitamins. J Clin Invest 1998; 102: 49.
  • 10
    Gattermann N, Dadak M, Hofhaus G, Wulfert M, Berneburg M, Loeffler ML, et al. Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration. Nucleosides Nucleotides Nucleic Acids 2004; 23: 12759.
  • 11
    Walker UA, Venhoff N, Koch E, Olschweski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003; 8: 46370.
  • 12
    Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, Caron M. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006; 11: 2534.
  • 13
    Banasch M, Goetze O, Knyhala K, Potthoff A, Schlottmann R, Kwiatek MA, et al. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS 2006; 20: 15546.
  • 14
    Sutinen J, Walker UA, Sevastianova K, Klinker H, Hakkinen AM, Ristola M, et al. Uridine for the treatment of antiviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007; 12: 97105.
  • 15
    Walker UA, Venhoff N. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 2005; 10 Suppl 2: M11723.
  • 16
    Venhoff N, Zilly M, Lebrecht D, Schirmer D, Klinker H, Thoden J, et al. Uridine pharmacokinetics of Mitocnol, a sugar cane extract. AIDS 2005; 19: 73940.
  • 17
    Lebrecht D, Vargas Infante YA, Setzer B, Kirschner J, Walker UA. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007; 15: 729.
  • 18
    Collins ML, Sondel N, Cesar D, Hellerstein MK. Effect of nucleoside reverse transcriptase inhibitors on mitochondrial DNA synthesis in rats and humans. J Acquir Immune Defic Syndr 2004; 37: 11329.
  • 19
    Deveaud C, Beauvoit B, Hagry S, Galinier A, Carriere A, Salin B, et al. Site specific alterations of adipose tissue mitochondria in 3′-azido-3′-deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy? Biochem Pharmacol 2005; 70: 90101.
  • 20
    Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003; 108: 24239.
  • 21
    Frings CS, Fendley TW, Dunn RT, Queen CA. Improved determination of total serum lipids by the sulfo-phospho-vanillin reaction. Clin Chem 1972; 18: 6734.
  • 22
    Silvestri G, Santorelli FM, Shanske S, Whitley CB, Schimmenti LA, Smith SA, et al. A new mtDNA mutation in the tRNALeu(UUR) gene associated with maternally inherited cardiomyopathy. Hum Mutat 1994; 3: 3743.
  • 23
    Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 216573.
  • 24
    Tuzgen S, Kaynar MY, Guner A, Gumustas K, Belce A, Etus V, et al. The effect of epidural cooling on lipid peroxidation after experimental spinal cord injury. Spinal Cord 1998; 36: 6547.
  • 25
    Poulton J, Sewry C, Potter CG, Bougeron T, Chretien D, Wijburg FA, et al. Variation in mitochondrial DNA levels in muscle from normal controls: is depletion of mtDNA in patients with mitochondrial myopathy a distinct clinical syndrome. J Inherit Metab Dis 1995; 18: 420.
  • 26
    Nohl H, Gille L, Staniek K. Intracellular generation of reactive oxygen species by mitochondria. Biochem Pharmacol 2005; 69: 71923.
  • 27
    Benbrik E, Chariot P, Bonavaud S, Ammi-Said M, Frisdal E, Rey C, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997; 149: 1925.
  • 28
    Pedrol E, Masanes F, Fernandez-Sola J, Cofan M, Casademont J, Grau JM, et al. Lack of muscle toxicity with didanosine (ddI): clinical and experimental studies. J Neurol Sci 1996; 138: 428.
  • 29
    Hosseini SH, Kohler JJ, Haase CP, Tioleco N, Stuart T, Keebaugh E, et al. Targeted transgenic overexpression of mitochondrial thymidine kinase (TK2) alters mitochondrial DNA (mtDNA) and mitochondrial polypeptide abundance: transgenic TK2, mtDNA, and antiretrovirals. Am J Pathol 2007; 170: 86574.
  • 30
    Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 1998; 53: 206.
  • 31
    Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999; 274: 360314.
  • 32
    Girot R, Hamet M, Perignon JL, Guesnu M, Fox RM, Cartier P, et al. Cellular immune deficiency in two siblings with hereditary orotic aciduria. N Engl J Med 1983; 308: 7004.
  • 33
    Sommadossi JP, Carlisle R, Schinazi RF, Zhou Z. Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother 1988; 32: 9971001.
  • 34
    Koch EC, Schneider J, Weiss R, Penning B, Walker UA. Uridine excess does not interfere with the antiretroviral efficacy of nucleoside analogue reverse transcriptase inhibitors. Antivir Ther 2003; 8: 4857.
  • 35
    McComsey GA, O'Riordan M, Setzer B, Lebrecht D, Baron E, Walker UA. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr 2007. E-pub ahead of print.